Kenya's Pharmaceutical Industry: Local Manufacturing, Drug Regulation, and the Push for Health Security

Kenya's pharmaceutical industry stands at a critical juncture, balancing between its heavy dependence on imported medicines and an ambitious government agenda to achieve pharmaceutical self-reliance. With a market valued at approximately $1 billion and projected revenues of US$565 million in 2024 growing to US$657 million by 2029, Kenya hosts one of the most dynamic pharmaceutical sectors in East Africa. The country is home to over 30 manufacturing plants, yet approximately 70 per cent of all finished drugs are still imported, and a staggering 95 per cent of active pharmaceutical ingredients (APIs) come from foreign sources—primarily India and China.

Overview of Kenya's Pharmaceutical Market

Kenya's pharmaceutical market is the largest in East Africa and serves as a regional hub for drug distribution across neighbouring countries including Uganda, Tanzania, Rwanda, and South Sudan. The market encompasses prescription medicines, over-the-counter drugs, vaccines, diagnostics, and medical devices. Kenyan manufacturers currently hold approximately 30 per cent of the domestic pharmaceutical market, according to the East African Community (EAC) Regional Pharmaceutical Plan of Action 2017–2027, with the remaining 70 per cent supplied through imports from India, Europe, the United States, and China.

The market is witnessing a surge in demand for locally produced generic drugs, driven by government procurement preferences, growing health insurance coverage under the Social Health Authority (SHA), and increasing consumer awareness about the quality of locally manufactured medicines. Kenya's strategic location, relatively advanced regulatory framework, and skilled workforce position it well to capture a larger share of both domestic and regional pharmaceutical markets.

Local Pharmaceutical Manufacturing

Kenya's pharmaceutical manufacturing sector comprises over 30 licensed facilities producing a range of products including tablets, capsules, syrups, injectables, and topical preparations. Major local manufacturers include Universal Corporation, Cosmos Pharmaceutical, Beta Healthcare, Dawa Limited, Regal Pharmaceuticals, Laboratory and Allied, and Biodeal Laboratories, among others. These companies produce essential medicines covering therapeutic areas such as antimalarials, antibiotics, antiretrovirals, analgesics, and cardiovascular drugs.

Despite this manufacturing base, production quantities of pharmaceutical products declined by 0.1 per cent in 2023 compared to an increase of 1.6 per cent in 2022, highlighting the challenges the sector faces. The decline reflects persistent obstacles including the high cost of imported raw materials, energy expenses, competition from cheaper imports, and limited access to affordable financing for capital expansion. Most local manufacturers operate as formulators—importing APIs and excipients to produce finished dosage forms—rather than engaging in primary chemical synthesis.

The absence of significant API manufacturing capacity remains the industry's most critical vulnerability. With 95 per cent of APIs imported, Kenyan manufacturers are exposed to global supply chain disruptions, currency fluctuations, and geopolitical risks. The COVID-19 pandemic starkly exposed this weakness when global supply chains were disrupted, causing medicine shortages and price spikes that threatened Kenya's health security.

The Regulatory Framework: Pharmacy and Poisons Board

The Pharmacy and Poisons Board (PPB) is Kenya's drug regulatory authority, established under the Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya. The Board regulates the practice of pharmacy, the manufacture and trade in drugs and poisons, and oversees the registration of pharmaceutical products, licensing of manufacturers and distributors, pharmacovigilance, and quality control testing.

The PPB has achieved WHO Maturity Level 3 status, making it one of the more advanced regulatory authorities on the African continent. This designation recognises the Board's capacity for effective regulatory oversight, including good manufacturing practice (GMP) inspections, product quality testing through its National Quality Control Laboratory (NQCL), and a structured product registration process. The PPB evaluates both locally manufactured and imported medicines before they can be marketed in Kenya, ensuring compliance with safety, efficacy, and quality standards.

Kenya is also a member of the African Medicines Regulatory Harmonization (AMRH) initiative under the African Union Development Agency, which aims to harmonize medicines regulation across the continent. Through the EAC Medicines Regulatory Harmonisation Programme, Kenya works with partner states to align registration requirements, enabling faster access to quality medicines across the region and reducing duplicative regulatory processes.

KEMSA and the Public Health Supply Chain

The Kenya Medical Supplies Authority (KEMSA) is the government agency responsible for procuring, warehousing, and distributing essential medicines and medical supplies to over 6,000 public health facilities across the country. As the leading wholesaler for the public sector, KEMSA plays a central role in ensuring the availability and affordability of medicines at government hospitals and dispensaries.

KEMSA operates a hub-and-spoke distribution model with a central warehouse in Nairobi and regional depots that supply county-level facilities. The agency has implemented an e-procurement system to improve transparency and efficiency, though it has faced governance challenges including the high-profile COVID-19 procurement scandal in 2020 that led to investigations and institutional reforms. Since then, KEMSA has undergone restructuring to strengthen internal controls and restore public confidence in its procurement processes.

The private pharmaceutical supply chain operates through a network of approximately 200 licensed importers and distributors, thousands of retail pharmacies, and hospital pharmacies. Major private sector distributors include Phillips Pharmaceuticals, Surgipharm, and Medisel, which supply both branded and generic medicines to private health facilities and retail outlets across the country.

Government Strategy for Pharmaceutical Self-Reliance

In October 2023, a presidential directive committed Kenya to locally manufacture at least 50 per cent of medicines on the Kenya Essential Medicines List (KEML) by 2026—an ambitious target that would dramatically expand local production capacity. Building on this directive, the government developed the Kenya Local Manufacturing Strategy 2025–2030, designed to scale up production and steer the country toward full self-reliance in Health Products and Technologies (HPTs).

Key components of the strategy include establishing a Pharmaceutical Development Fund to provide loans and financial support to local manufacturers, creating tax incentives for pharmaceutical investments, streamlining regulatory processes for locally manufactured products, and investing in workforce development through pharmacy schools and technical training institutions. The Ministry of Health has been leading coordination efforts across multiple government agencies to align industrial, health, and trade policies in support of this agenda.

The government has also prioritised the development of API manufacturing capacity, recognizing that true pharmaceutical independence requires upstream chemical synthesis capabilities. Initiatives to attract investment in API production include designating pharmaceutical manufacturing as a priority sector under the Special Economic Zones framework, offering enhanced incentives for API manufacturers, and exploring public-private partnerships to establish Kenya's first large-scale API production facilities.

Challenges Facing the Industry

Despite the favourable policy environment, Kenya's pharmaceutical sector faces significant structural challenges. The cost of manufacturing in Kenya remains higher than in major generic-producing countries like India, owing to expensive imported raw materials, high energy costs, and relatively small production volumes that limit economies of scale. Local manufacturers also face intense competition from imported generics, particularly from India, which dominates the global generic drugs market and offers products at extremely competitive prices.

Access to affordable long-term financing remains a persistent barrier. Pharmaceutical manufacturing is capital-intensive, requiring significant investment in GMP-compliant facilities, quality control equipment, and skilled personnel. Kenyan manufacturers often struggle to access financing at commercially viable interest rates, limiting their ability to expand capacity or upgrade to higher-value product lines such as sterile injectables, biologics, or vaccines.

Intellectual property and technology transfer challenges also constrain the sector. While generic drug production relies on accessing off-patent molecules, the development of biosimilars and complex generics requires sophisticated technical capabilities that are still emerging in Kenya. Strengthening research and development capacity through institutions like the Kenya Medical Research Institute (KEMRI) and university pharmacy programmes is essential for the industry's long-term competitiveness.

The Future of Kenya's Pharmaceutical Sector

Kenya's pharmaceutical industry stands at the threshold of significant transformation. The convergence of strong political will, an ambitious national manufacturing strategy, regional market integration under the AfCFTA, and growing domestic demand driven by expanding health insurance coverage creates a compelling opportunity for sector growth. If the government's target of 50 per cent local production of essential medicines is achieved by 2026, it would represent a historic shift in Kenya's health security landscape.

The development of vaccine manufacturing capacity represents another frontier. The COVID-19 pandemic catalysed global interest in distributed vaccine production, and several African countries including Kenya are exploring partnerships with international pharmaceutical companies to establish local vaccine production lines. Such investments would not only enhance pandemic preparedness but also address routine immunization needs across the region.

With the right combination of policy support, investment incentives, regulatory efficiency, and workforce development, Kenya has the potential to emerge as Africa's leading pharmaceutical manufacturing hub—producing quality medicines not only for its own population but for the broader African market of over 1.4 billion people.